Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Papaverine for Refractory Taxane-Induced Peripheral Neuropathy
NCT07572461Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of papaverine in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Change from baseline in EORTC QLQ-CIPN20 sensory scale score at Day 15. Planned start May 2026; status: not yet recruiting.
02
Drugs
papaverine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT07572461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572461.